{"id":6598,"date":"2026-09-07T23:22:17","date_gmt":"2026-09-07T21:22:17","guid":{"rendered":"https:\/\/wellnessforum.pro\/?p=6598"},"modified":"2026-09-07T23:22:19","modified_gmt":"2026-09-07T21:22:19","slug":"psilocybin-and-depression-the-psychedelic-therapy-that-is-beginning-to-enter-medicine","status":"publish","type":"post","link":"https:\/\/wellnessforum.pro\/en\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/","title":{"rendered":"Psilocybin and depression: the psychedelic therapy beginning to enter mainstream medicine"},"content":{"rendered":"

Clinical research is accumulating increasingly solid evidence on the antidepressant potential of psilocybin, especially in people with treatment-resistant depression. Australia allows its use under highly restricted conditions, and Oregon has created a regulated psychedelic services system. In Spain, its therapeutic use remains limited to authorized research.<\/em><\/p>\n\n\n\n

For decades, psilocybin was associated with psychedelic culture and recreational use. Psychiatry's interest in this substance, however, has a considerably older history. During the 1950s and 1960s, some of the first clinical experiments with psychedelics were conducted before regulatory restrictions brought virtually all research to a halt for several decades.<\/p>\n\n\n\n

The situation began to shift at the end of the 20th century and, much more visibly, over the past fifteen years. Universities, hospitals, and pharmaceutical companies have resumed the study of psilocybin using methods consistent with modern clinical research. The results obtained so far explain why the substance has come to occupy a relevant place in the debate about the future of depression treatments.<\/p>\n\n\n\n

A meta-analysis published in 2025 in Acta Psychiatrica Scandinavica<\/em>, which pooled six randomized clinical trials and 427 participants, found a reduction in depressive symptoms significantly greater than that observed in control groups. The likelihood of clinical response was approximately 3.4 times higher, and the likelihood of remission 3.7 times higher, among patients treated with psilocybin.<\/p>\n\n\n\n

The results are especially interesting in patients with treatment-resistant depression, a group in which therapeutic options can be limited after several pharmacological and psychotherapeutic treatments without an adequate response.<\/p>\n\n\n\n

The session lasts hours and requires supervision<\/h3>\n\n\n\n

Clinical protocols have little in common with the image of someone taking psilocybin at home to improve their mood. The substance is administered at a specific dose, within a prepared setting, and after a medical and psychological evaluation. The patient remains accompanied for several hours while the acute effect lasts, and subsequently attends sessions aimed at processing and integrating the experience.<\/p>\n\n\n\n

Prior preparation plays an important role. The therapeutic team explains what the patient may experience, reviews their medical and psychiatric history, analyzes the medication they are taking, and establishes the necessary conditions for the session to take place safely.<\/p>\n\n\n\n

During administration, the person may experience very intense alterations in perception, sense of time, and sense of self, as well as emotional and cognitive changes. The duration and intensity depend on the dose and individual characteristics, but clinical sessions require several hours precisely because the effect does not wear off quickly.<\/p>\n\n\n\n

The follow-up work completes the protocol. Integration sessions allow the patient to review what happened and connect it to the psychological issues that led them to treatment.<\/p>\n\n\n\n

This structure also explains why researchers usually speak of psilocybin-assisted therapy<\/strong> rather than simply pharmacological treatment with psilocybin.<\/p>\n\n\n\n

Debate still exists over the exact contribution of each element. Psilocybin produces significant neurobiological and subjective changes, while the therapeutic context can influence how those changes translate into modifications in behavior, emotions, and certain thought patterns.<\/p>\n\n\n\n

Australia: psilocybin within a medical protocol<\/h3>\n\n\n\n

Australia offers one of the most advanced examples of clinical regulation.<\/p>\n\n\n\n

Since July 2023, certain psychiatrists can use psilocybin for patients with treatment-resistant depression under the Authorised Prescriber<\/em> scheme of the Therapeutic Goods Administration. The system requires specific authorization and supervision within a clinical protocol. Psilocybin remains a medicine not approved by the TGA for general marketing.<\/p>\n\n\n\n

The intervention requires an appropriate clinical setting and trained professionals to accompany the patient. Administration also does not follow the pattern of a conventional prescription: the patient does not simply receive a medication to take at home.<\/p>\n\n\n\n

During 2026, Australia introduced some changes to the conditions regulating these treatments, including aspects related to medical supervision and the composition of therapeutic teams. The framework remains restrictive and is primarily aimed at patients with severe conditions resistant to available treatments.<\/p>\n\n\n\n

The Australian model is relevant because it represents one of the first occasions on which a national regulator has allowed a psychedelic to be used clinically for a specific psychiatric indication under the responsibility of authorized specialists.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Oregon has created another model<\/h3>\n\n\n\n

In the United States, the situation requires more careful explanation because there are significant differences between federal legislation and certain state programs.<\/p>\n\n\n\n

Oregon has allowed since 2023 the so-called psilocybin services<\/em>.<\/a> People over 21 can access them without a medical prescription or a depression diagnosis, but they must complete a preparation session and an administration session at a licensed center, followed by an integration phase.<\/p>\n\n\n\n

The system has a particularly relevant feature: psilocybin is consumed within the facility and cannot be legally purchased to take home. During the session, the user remains accompanied by a licensed facilitator.<\/p>\n\n\n\n

This model also does not amount to an FDA pharmacological approval of psilocybin for depression. Oregon's state regulation and U.S. federal legislation operate on different levels.<\/p>\n\n\n\n

For that reason, when talking about the United States, it's important to distinguish between clinical trials studying psilocybin as a medication and Oregon's psychedelic services program, which responds to specific state legislation.<\/p>\n\n\n\n

Spain keeps the substance under control<\/h3>\n\n\n\n

Spain holds a far more active position in psychedelic research than its regulatory situation might suggest. Psilocybin and psilocin are listed in Schedule I of psychotropic substances under control in Spain, according to Royal Decree 2829\/1977, meaning their use, manufacturing, distribution, prescription, and possession are subject to a specific control regime; this does not, however, prevent their use within authorized clinical research. <\/p>\n\n\n\n

The most developed case is found at the Parc Sanitari Sant Joan de D\u00e9u<\/a>, in Barcelona, where the ANIMA research group has been working with psychedelics and treatment-resistant depression for several years. The center conducted two phase II trials with psilocybin in 2021 and subsequently expanded this line with studies incorporating psilocybin and 5-MeO-DMT<\/a>, in collaboration with companies such as Compass Pathways, Beckley Psytech, and GH Research. <\/p>\n\n\n\n

In these protocols, administration takes place in a controlled hospital setting, accompanied by psychotherapeutic support and with follow-up afterward, and not as a prescription the patient can take home. Spanish research has also been integrated into the international phase III program of COMP360, the psilocybin formulation developed by Compass Pathways for treatment-resistant depression: the NCT05711940 trial, with 572 participants, included Spanish centers such as Hospital Cl\u00ednic de Barcelona, Parc Sanitari Sant Joan de D\u00e9u, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz in Madrid, FIDMAG Hermanas Hospitalarias, Hospital Universitario R\u00edo Hortega in Valladolid, and Hospital Provincial de Zamora, among other international centers. <\/p>\n\n\n\n

The study compares administrations of 25, 10, and 1 mg of COMP360 alongside psychological support and includes follow-up of up to 52 weeks. This activity makes it possible to state that psilocybin is already being administered to patients with depression in Spain within certain clinical trials, but not that a psilocybin therapy is yet available as a conventional medical treatment: outside an authorized study, a Spanish psychiatrist cannot simply prescribe psilocybin for a patient to consume at home or administer it as standard treatment in a private practice. <\/p>\n\n\n\n

The difference is fundamental. Spain is participating in generating the evidence that could support a future authorization, but, as of September 2026, psilocybin remains an investigational product and not an authorized medication for treating depression in ordinary clinical practice.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Why might it work?<\/h3>\n\n\n\n

Psilocybin is transformed into psilocin once ingested. This molecule acts primarily on 5-HT2A serotonergic receptors, which are involved in processes related to perception, cognition, and emotional regulation.<\/p>\n\n\n\n

The biological explanation for the antidepressant effect is still being investigated. One of the most studied hypotheses links the psychedelic experience to transient changes in certain brain circuits and to an increase in neuronal and psychological plasticity.<\/p>\n\n\n\n

During the experience, certain rigid and repetitive thought patterns may temporarily decrease. In people with depression, this could facilitate a revision of certain negative associations, memories, and emotional patterns that have persisted over long periods.<\/p>\n\n\n\n

Research on neuroplasticity has generated particular interest because it offers a possible explanation for the speed with which some patients improve after one or two sessions. Conventional antidepressants usually need several weeks to reach their full therapeutic effect, while some psilocybin trials have observed significant changes just days after administration.<\/p>\n\n\n\n

The hypothesis still needs confirmation. Researchers have also not determined how much the outcome depends on the pharmacological action and how much on the subjective experience and therapeutic context.<\/p>\n\n\n\n

The numbers are promising, but not uniform<\/h3>\n\n\n\n

One of the first controlled trials to spark considerable interest was conducted by researchers at Johns Hopkins in patients with major depression. Two psilocybin sessions accompanied by psychological support produced a clinical response in 71% of participants and remission in 54% at four weeks. The small sample size requires interpreting these percentages with caution.<\/p>\n\n\n\n

Los trabajos posteriores han ampliado la evidencia. El metaan\u00e1lisis publicado en 2025 confirm\u00f3 un efecto antidepresivo significativo y una mayor probabilidad de respuesta y remisi\u00f3n frente a los controles. Otros an\u00e1lisis han encontrado resultados similares, aunque con diferencias importantes entre estudios relacionadas con las dosis, el tipo de pacientes, los comparadores y el dise\u00f1o de las sesiones.<\/p>\n\n\n\n

Una de las dificultades metodol\u00f3gicas m\u00e1s conocidas de la investigaci\u00f3n psicod\u00e9lica es el cegamiento. Una persona que recibe una dosis suficientemente alta de psilocibina suele percibir que ha recibido una sustancia activa, lo que dificulta mantener completamente ciego el ensayo. Las expectativas del paciente pueden influir en su percepci\u00f3n de los efectos y en determinadas medidas subjetivas.<\/p>\n\n\n\n

Los estudios m\u00e1s recientes est\u00e1n intentando reducir este problema mediante dise\u00f1os m\u00e1s sofisticados y grupos de control activos.<\/p>\n\n\n\n

El salto hacia los ensayos de fase III<\/h3>\n\n\n\n

La investigaci\u00f3n ha entrado adem\u00e1s en una etapa mucho m\u00e1s avanzada con los programas de desarrollo farmac\u00e9utico de compa\u00f1\u00edas como Compass Pathways<\/a>.<\/p>\n\n\n\n

Su compuesto COMP360, una formulaci\u00f3n sint\u00e9tica de psilocibina, ha sido estudiado en ensayos de fase III en depresi\u00f3n resistente. En 2026, la compa\u00f1\u00eda comunic\u00f3 resultados positivos de su segundo ensayo pivotal, con una reducci\u00f3n cl\u00ednicamente relevante de los s\u00edntomas en una proporci\u00f3n significativa de los pacientes tratados con 25 mg.<\/p>\n\n\n\n

Los datos comunicados por la compa\u00f1\u00eda indican que aproximadamente el 39% de los pacientes que recibieron 25 mg alcanz\u00f3 el criterio de respuesta definido en el estudio en la semana seis y que parte del beneficio permaneci\u00f3 durante el seguimiento posterior.<\/p>\n\n\n\n

Estos resultados todav\u00eda deben interpretarse dentro del contexto de un programa de desarrollo farmac\u00e9utico en curso y de los datos completos que deber\u00e1n ser evaluados por los reguladores. Aun as\u00ed, el hecho de que la investigaci\u00f3n haya llegado a fase III marca una diferencia sustancial respecto a los primeros estudios exploratorios realizados con muestras muy peque\u00f1as.<\/p>\n\n\n\n

El inter\u00e9s de las autoridades sanitarias tambi\u00e9n ha aumentado. La FDA ha introducido medidas destinadas a acelerar el desarrollo de tratamientos psicod\u00e9licos para enfermedades mentales graves, dentro de un contexto m\u00e1s amplio de investigaci\u00f3n de nuevas alternativas terap\u00e9uticas.<\/p>\n\n\n\n

Los riesgos obligan a seleccionar cuidadosamente al paciente<\/h3>\n\n\n\n

El perfil de seguridad observado en los ensayos cl\u00ednicos ha sido razonablemente favorable cuando los participantes han sido seleccionados siguiendo criterios estrictos y las sesiones se han desarrollado bajo supervisi\u00f3n.<\/p>\n\n\n\n

Los efectos adversos m\u00e1s habituales incluyen cefalea, n\u00e1useas, mareo, ansiedad y aumentos transitorios de la presi\u00f3n arterial y de la frecuencia card\u00edaca. Tambi\u00e9n pueden aparecer alteraciones perceptivas intensas y episodios de miedo o angustia durante la experiencia.<\/p>\n\n\n\n

La selecci\u00f3n previa del paciente resulta especialmente importante en este tratamiento. Los protocolos excluyen habitualmente a personas con determinados antecedentes de psicosis, determinados trastornos bipolares u otras condiciones que puedan aumentar el riesgo de una reacci\u00f3n psiqui\u00e1trica adversa.<\/p>\n\n\n\n

La diferencia entre una sesi\u00f3n cl\u00ednica supervisada y el consumo de psilocibina fuera de un entorno sanitario resulta especialmente relevante en este punto. En un ensayo, la dosis est\u00e1 definida, la sustancia est\u00e1 caracterizada, el paciente ha sido evaluado y existe personal preparado para intervenir. En el consumo no regulado pueden faltar todos esos elementos.<\/p>\n\n\n\n

Tampoco conocemos todav\u00eda con la misma profundidad los posibles efectos de exposiciones repetidas durante periodos prolongados. Los ensayos realizados hasta ahora proporcionan informaci\u00f3n importante sobre la seguridad de determinados protocolos, pero no permiten extrapolar sus resultados a cualquier forma de consumo.<\/p>\n\n\n\n

El tratamiento es caro porque requiere tiempo profesional<\/h3>\n\n\n\n

El precio constituye otro de los obst\u00e1culos para la expansi\u00f3n de este tipo de terapia.<\/p>\n\n\n\n

En Espa\u00f1a no existe un precio terap\u00e9utico oficial porque la psilocibina no est\u00e1 autorizada como medicamento para la depresi\u00f3n. Cualquier cifra atribuida a un supuesto \u201cprecio del tratamiento con psilocibina en Espa\u00f1a\u201d mezclar\u00eda necesariamente modelos legales con ofertas no reguladas.<\/p>\n\n\n\n

Oreg\u00f3n ofrece una referencia m\u00e1s \u00fatil porque existe un mercado legal de servicios psicod\u00e9licos. Los precios dependen de cada centro y pueden variar considerablemente, aunque las estimaciones disponibles sit\u00faan muchas sesiones completas aproximadamente entre 1.000 y 3.500 d\u00f3lares.<\/p>\n\n\n\n

La mayor parte del coste no corresponde a la sustancia. Una sesi\u00f3n requiere horas de presencia profesional, instalaciones adecuadas, preparaci\u00f3n previa y seguimiento posterior. El tratamiento exige una infraestructura mucho m\u00e1s intensiva en tiempo que la dispensaci\u00f3n convencional de un antidepresivo.<\/p>\n\n\n\n

Esta caracter\u00edstica tendr\u00e1 importancia si la psilocibina llega a obtener una autorizaci\u00f3n farmac\u00e9utica. El modelo econ\u00f3mico de una terapia que requiere varias horas de supervisi\u00f3n y profesionales especializados ser\u00e1 necesariamente diferente del de un medicamento que el paciente recoge en una farmacia y toma diariamente.<\/p>\n\n\n\n

Una posible nueva herramienta para la depresi\u00f3n resistente<\/h3>\n\n\n\n

La investigaci\u00f3n sobre psilocibina ha alcanzado un punto en el que resulta dif\u00edcil considerar el fen\u00f3meno una simple moda pasajera. Existen ensayos controlados, metaan\u00e1lisis, programas de fase III y dos pa\u00edses que han desarrollado marcos regulatorios para permitir determinadas formas de utilizaci\u00f3n.<\/p>\n\n\n\n

Al mismo tiempo, quedan preguntas importantes por responder. Falta determinar qu\u00e9 pacientes presentan una mayor probabilidad de respuesta, cu\u00e1nto tiempo puede mantenerse la mejor\u00eda, cu\u00e1l es la dosis \u00f3ptima, cu\u00e1ntas sesiones son necesarias y qu\u00e9 papel exacto desempe\u00f1a la psicoterapia.<\/p>\n\n\n\n

Tambi\u00e9n habr\u00e1 que determinar c\u00f3mo encajar\u00eda un tratamiento de estas caracter\u00edsticas dentro de los sistemas sanitarios. Una intervenci\u00f3n de varias horas, acompa\u00f1ada por profesionales y seguida de sesiones de integraci\u00f3n, requiere recursos muy diferentes de los que necesita la prescripci\u00f3n de un antidepresivo convencional.<\/p>\n\n\n\n

La investigaci\u00f3n disponible permite hablar de un potencial terap\u00e9utico considerable, especialmente para personas con depresi\u00f3n resistente, pero todav\u00eda resulta prematuro presentar la psilocibina como una soluci\u00f3n general para la depresi\u00f3n.<\/p>\n\n\n\n

El escenario que se est\u00e1 dibujando es m\u00e1s espec\u00edfico y, probablemente, m\u00e1s interesante: un tratamiento en el que una sustancia psicod\u00e9lica cuidadosamente dosificada puede abrir una ventana temporal de cambio psicol\u00f3gico, mientras el entorno cl\u00ednico y el trabajo terap\u00e9utico ayudan al paciente a aprovecharla.<\/p>\n\n\n\n

Australia ha decidido permitir ese modelo bajo un r\u00e9gimen m\u00e9dico muy restringido. Oreg\u00f3n ha construido una alternativa basada en servicios psicod\u00e9licos regulados. Europa contin\u00faa estudiando la sustancia dentro de los l\u00edmites de la investigaci\u00f3n cl\u00ednica. Espa\u00f1a, por el momento, mantiene la psilocibina bajo fiscalizaci\u00f3n y fuera de la pr\u00e1ctica asistencial ordinaria.<\/p>\n\n\n\n

Los resultados de los grandes ensayos que est\u00e1n llegando ahora ser\u00e1n determinantes. Si confirman los beneficios observados en las investigaciones anteriores, los reguladores tendr\u00e1n que decidir no solamente si autorizan la mol\u00e9cula, sino tambi\u00e9n c\u00f3mo debe administrarse, qui\u00e9n puede hacerlo y qu\u00e9 lugar debe ocupar la psicoterapia dentro del tratamiento<\/strong>.<\/p>\n\n\n\n

Estudios cient\u00edficos de referencia:<\/p>\n\n\n\n

https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2808950?guestAccessKey=ed25fe13-871d-42e7-8fa0-a56171882<\/a><\/p>\n\n\n\n

https:\/\/www.bmj.com\/content\/385\/bmj-2023-078084<\/a><\/p>\n\n\n\n

https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849099<\/a><\/p>\n\n\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

La investigaci\u00f3n cl\u00ednica acumula resultados cada vez m\u00e1s s\u00f3lidos sobre el potencial antidepresivo de la psilocibina, especialmente en personas con depresi\u00f3n resistente. Australia permite su utilizaci\u00f3n bajo condiciones muy restringidas y Oreg\u00f3n ha creado un sistema regulado de servicios psicod\u00e9licos. En Espa\u00f1a, su uso terap\u00e9utico permanece limitado a la investigaci\u00f3n autorizada. Durante d\u00e9cadas, la psilocibina […]<\/p>\n","protected":false},"author":2,"featured_media":6599,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73,25],"tags":[],"class_list":["post-6598","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mental","category-salud"],"yoast_head":"\nPsilocibina y depresi\u00f3n: la terapia psicod\u00e9lica que empieza a entrar en la medicina<\/title>\n<meta name=\"description\" content=\"La psilocibina y la psilocina figuran en la Lista I de sustancias psicotr\u00f3picas sometidas a fiscalizaci\u00f3n de acuerdo con el Real Decreto\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wellnessforum.pro\/en\/psilocybin-and-depression-the-psychedelic-therapy-that-is-beginning-to-enter-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Psilocibina y depresi\u00f3n: la terapia psicod\u00e9lica que empieza a entrar en la medicina\" \/>\n<meta property=\"og:description\" content=\"La psilocibina y la psilocina figuran en la Lista I de sustancias psicotr\u00f3picas sometidas a fiscalizaci\u00f3n de acuerdo con el Real Decreto\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wellnessforum.pro\/en\/psilocybin-and-depression-the-psychedelic-therapy-that-is-beginning-to-enter-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Wellness Forum\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-07T21:22:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-07T21:22:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/wellnessforum.pro\/wp-content\/uploads\/2026\/09\/Terapia-con-alucinogenos-la-psilocibina-podria-reducir-los-comportamientos-obsesivo-compulsivos.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nadia Tresoro\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nadia Tresoro\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/\"},\"author\":{\"name\":\"Nadia Tresoro\",\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/#\\\/schema\\\/person\\\/d9ff1cceff0b8f1d118cb255379e1e8e\"},\"headline\":\"Psilocibina y depresi\u00f3n: la terapia psicod\u00e9lica que empieza a entrar en la medicina\",\"datePublished\":\"2026-09-07T21:22:17+00:00\",\"dateModified\":\"2026-09-07T21:22:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/\"},\"wordCount\":2998,\"publisher\":{\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/wellnessforum.pro\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Terapia-con-alucinogenos-la-psilocibina-podria-reducir-los-comportamientos-obsesivo-compulsivos.jpg\",\"articleSection\":[\"Mental\",\"Salud\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/\",\"url\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/\",\"name\":\"Psilocibina y depresi\u00f3n: la terapia psicod\u00e9lica que empieza a entrar en la medicina\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/wellnessforum.pro\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Terapia-con-alucinogenos-la-psilocibina-podria-reducir-los-comportamientos-obsesivo-compulsivos.jpg\",\"datePublished\":\"2026-09-07T21:22:17+00:00\",\"dateModified\":\"2026-09-07T21:22:19+00:00\",\"description\":\"La psilocibina y la psilocina figuran en la Lista I de sustancias psicotr\u00f3picas sometidas a fiscalizaci\u00f3n de acuerdo con el Real Decreto\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/#primaryimage\",\"url\":\"https:\\\/\\\/wellnessforum.pro\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Terapia-con-alucinogenos-la-psilocibina-podria-reducir-los-comportamientos-obsesivo-compulsivos.jpg\",\"contentUrl\":\"https:\\\/\\\/wellnessforum.pro\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Terapia-con-alucinogenos-la-psilocibina-podria-reducir-los-comportamientos-obsesivo-compulsivos.jpg\",\"width\":1200,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/wellnessforum.pro\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salud\",\"item\":\"https:\\\/\\\/wellnessforum.pro\\\/salud\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Psilocibina y depresi\u00f3n: la terapia psicod\u00e9lica que empieza a entrar en la medicina\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/#website\",\"url\":\"https:\\\/\\\/wellnessforum.pro\\\/\",\"name\":\"Wellness Forum\",\"description\":\"\u00bfQuieres una vida m\u00e1s saludable y pr\u00f3spera? Visita Wellness Forum y encuentra las mejores gu\u00edas y consejos en salud, bienestar y riqueza. \u00a1Empieza tu transformaci\u00f3n!\",\"publisher\":{\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/wellnessforum.pro\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/#organization\",\"name\":\"Wellness Forum\",\"url\":\"https:\\\/\\\/wellnessforum.pro\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/wellnessforum.pro\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/160LOGO-WF.png\",\"contentUrl\":\"https:\\\/\\\/wellnessforum.pro\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/160LOGO-WF.png\",\"width\":235,\"height\":160,\"caption\":\"Wellness Forum\"},\"image\":{\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/wellnessforum.pro\\\/#\\\/schema\\\/person\\\/d9ff1cceff0b8f1d118cb255379e1e8e\",\"name\":\"Nadia Tresoro\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1f61d2512baeae917923e36d03cd5d197e8a08ee8f8b2a41dcc1f094e26312c4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1f61d2512baeae917923e36d03cd5d197e8a08ee8f8b2a41dcc1f094e26312c4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1f61d2512baeae917923e36d03cd5d197e8a08ee8f8b2a41dcc1f094e26312c4?s=96&d=mm&r=g\",\"caption\":\"Nadia Tresoro\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Psilocybin and depression: the psychedelic therapy beginning to enter mainstream medicine","description":"Psilocybin and psilocin are listed in Schedule I of psychotropic substances subject to control in accordance with the Royal Decree","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wellnessforum.pro\/en\/psilocybin-and-depression-the-psychedelic-therapy-that-is-beginning-to-enter-medicine\/","og_locale":"en_GB","og_type":"article","og_title":"Psilocibina y depresi\u00f3n: la terapia psicod\u00e9lica que empieza a entrar en la medicina","og_description":"La psilocibina y la psilocina figuran en la Lista I de sustancias psicotr\u00f3picas sometidas a fiscalizaci\u00f3n de acuerdo con el Real Decreto","og_url":"https:\/\/wellnessforum.pro\/en\/psilocybin-and-depression-the-psychedelic-therapy-that-is-beginning-to-enter-medicine\/","og_site_name":"Wellness Forum","article_published_time":"2026-09-07T21:22:17+00:00","article_modified_time":"2026-09-07T21:22:19+00:00","og_image":[{"width":1200,"height":900,"url":"https:\/\/wellnessforum.pro\/wp-content\/uploads\/2026\/09\/Terapia-con-alucinogenos-la-psilocibina-podria-reducir-los-comportamientos-obsesivo-compulsivos.jpg","type":"image\/jpeg"}],"author":"Nadia Tresoro","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nadia Tresoro","Estimated reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/#article","isPartOf":{"@id":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/"},"author":{"name":"Nadia Tresoro","@id":"https:\/\/wellnessforum.pro\/#\/schema\/person\/d9ff1cceff0b8f1d118cb255379e1e8e"},"headline":"Psilocibina y depresi\u00f3n: la terapia psicod\u00e9lica que empieza a entrar en la medicina","datePublished":"2026-09-07T21:22:17+00:00","dateModified":"2026-09-07T21:22:19+00:00","mainEntityOfPage":{"@id":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/"},"wordCount":2998,"publisher":{"@id":"https:\/\/wellnessforum.pro\/#organization"},"image":{"@id":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/#primaryimage"},"thumbnailUrl":"https:\/\/wellnessforum.pro\/wp-content\/uploads\/2026\/09\/Terapia-con-alucinogenos-la-psilocibina-podria-reducir-los-comportamientos-obsesivo-compulsivos.jpg","articleSection":["Mental","Salud"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/","url":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/","name":"Psilocybin and depression: the psychedelic therapy beginning to enter mainstream medicine","isPartOf":{"@id":"https:\/\/wellnessforum.pro\/#website"},"primaryImageOfPage":{"@id":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/#primaryimage"},"image":{"@id":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/#primaryimage"},"thumbnailUrl":"https:\/\/wellnessforum.pro\/wp-content\/uploads\/2026\/09\/Terapia-con-alucinogenos-la-psilocibina-podria-reducir-los-comportamientos-obsesivo-compulsivos.jpg","datePublished":"2026-09-07T21:22:17+00:00","dateModified":"2026-09-07T21:22:19+00:00","description":"Psilocybin and psilocin are listed in Schedule I of psychotropic substances subject to control in accordance with the Royal Decree","breadcrumb":{"@id":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/#primaryimage","url":"https:\/\/wellnessforum.pro\/wp-content\/uploads\/2026\/09\/Terapia-con-alucinogenos-la-psilocibina-podria-reducir-los-comportamientos-obsesivo-compulsivos.jpg","contentUrl":"https:\/\/wellnessforum.pro\/wp-content\/uploads\/2026\/09\/Terapia-con-alucinogenos-la-psilocibina-podria-reducir-los-comportamientos-obsesivo-compulsivos.jpg","width":1200,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/wellnessforum.pro\/psilocibina-y-depresion-la-terapia-psicodelica-que-empieza-a-entrar-en-la-medicina\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/wellnessforum.pro\/"},{"@type":"ListItem","position":2,"name":"Salud","item":"https:\/\/wellnessforum.pro\/salud\/"},{"@type":"ListItem","position":3,"name":"Psilocibina y depresi\u00f3n: la terapia psicod\u00e9lica que empieza a entrar en la medicina"}]},{"@type":"WebSite","@id":"https:\/\/wellnessforum.pro\/#website","url":"https:\/\/wellnessforum.pro\/","name":"Wellness Forum","description":"Do you want a healthier and more prosperous life? Visit the Wellness Forum and find the best guides and advice on health, wellness and wealth - start your transformation!","publisher":{"@id":"https:\/\/wellnessforum.pro\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wellnessforum.pro\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/wellnessforum.pro\/#organization","name":"Wellness Forum","url":"https:\/\/wellnessforum.pro\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/wellnessforum.pro\/#\/schema\/logo\/image\/","url":"https:\/\/wellnessforum.pro\/wp-content\/uploads\/2023\/09\/160LOGO-WF.png","contentUrl":"https:\/\/wellnessforum.pro\/wp-content\/uploads\/2023\/09\/160LOGO-WF.png","width":235,"height":160,"caption":"Wellness Forum"},"image":{"@id":"https:\/\/wellnessforum.pro\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/wellnessforum.pro\/#\/schema\/person\/d9ff1cceff0b8f1d118cb255379e1e8e","name":"Nadia Tresoro","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/1f61d2512baeae917923e36d03cd5d197e8a08ee8f8b2a41dcc1f094e26312c4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1f61d2512baeae917923e36d03cd5d197e8a08ee8f8b2a41dcc1f094e26312c4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1f61d2512baeae917923e36d03cd5d197e8a08ee8f8b2a41dcc1f094e26312c4?s=96&d=mm&r=g","caption":"Nadia Tresoro"}}]}},"_links":{"self":[{"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/posts\/6598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/comments?post=6598"}],"version-history":[{"count":1,"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/posts\/6598\/revisions"}],"predecessor-version":[{"id":6602,"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/posts\/6598\/revisions\/6602"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/media\/6599"}],"wp:attachment":[{"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/media?parent=6598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/categories?post=6598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wellnessforum.pro\/en\/wp-json\/wp\/v2\/tags?post=6598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}